DE602006018590D1 - Heteroarylharnstoffderivate zur hemmung von chk1 - Google Patents

Heteroarylharnstoffderivate zur hemmung von chk1

Info

Publication number
DE602006018590D1
DE602006018590D1 DE602006018590T DE602006018590T DE602006018590D1 DE 602006018590 D1 DE602006018590 D1 DE 602006018590D1 DE 602006018590 T DE602006018590 T DE 602006018590T DE 602006018590 T DE602006018590 T DE 602006018590T DE 602006018590 D1 DE602006018590 D1 DE 602006018590D1
Authority
DE
Germany
Prior art keywords
heteroaryl
drug derivatives
inhibiting chk1
chk1
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602006018590T
Other languages
German (de)
English (en)
Inventor
Frank Diaz
Francine S Farouz
Ryan Holcomb
Edward A Kesicki
Hua Chee Ooi
Alexander Rudolph
Frank Stappenbeck
Eugene Thorsett
John Joseph Gaudino
Kimba L Fisher
Adam Wade Cook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icos Corp
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Publication of DE602006018590D1 publication Critical patent/DE602006018590D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
DE602006018590T 2005-03-29 2006-03-29 Heteroarylharnstoffderivate zur hemmung von chk1 Expired - Lifetime DE602006018590D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66602605P 2005-03-29 2005-03-29
PCT/US2006/011584 WO2006105262A1 (en) 2005-03-29 2006-03-29 HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl

Publications (1)

Publication Number Publication Date
DE602006018590D1 true DE602006018590D1 (de) 2011-01-13

Family

ID=36677174

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006018590T Expired - Lifetime DE602006018590D1 (de) 2005-03-29 2006-03-29 Heteroarylharnstoffderivate zur hemmung von chk1

Country Status (31)

Country Link
US (1) US8093244B2 (https=)
EP (2) EP1869020B1 (https=)
JP (2) JP5117374B2 (https=)
KR (2) KR100912998B1 (https=)
CN (2) CN101151259B (https=)
AR (1) AR056645A1 (https=)
AT (1) ATE490248T1 (https=)
AU (1) AU2006230337B2 (https=)
BR (1) BRPI0609667A2 (https=)
CA (1) CA2602199C (https=)
CR (1) CR9395A (https=)
CY (1) CY1111240T1 (https=)
DE (1) DE602006018590D1 (https=)
DK (1) DK1869020T3 (https=)
EA (1) EA011287B1 (https=)
ES (1) ES2356068T3 (https=)
HR (1) HRP20100678T1 (https=)
IL (1) IL185481A0 (https=)
MA (1) MA29439B1 (https=)
MX (1) MX2007012116A (https=)
NO (1) NO20074944L (https=)
NZ (1) NZ561458A (https=)
PL (1) PL1869020T3 (https=)
PT (1) PT1869020E (https=)
RS (1) RS51616B (https=)
SI (1) SI1869020T1 (https=)
TN (1) TNSN07369A1 (https=)
TW (1) TWI375559B (https=)
UA (1) UA92164C2 (https=)
WO (1) WO2006105262A1 (https=)
ZA (1) ZA200707715B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221367A (en) 1988-08-03 1993-06-22 International Business Machines, Corp. Strained defect-free epitaxial mismatched heterostructures and method of fabrication
WO2008067027A2 (en) * 2006-10-20 2008-06-05 Icos Corporation Compositions of chkl inhibitors and cyclodextrin
CN101200429B (zh) * 2006-12-13 2012-08-22 上海睿智化学研究有限公司 2-硝基-4,5-二卤代苯酚类和2-氨基-4,5-二卤代苯酚类及其盐及其合成方法
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
SG11201610500WA (en) 2014-06-17 2017-01-27 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
CN108601781B (zh) 2016-02-04 2019-11-22 广州必贝特医药技术有限公司 作为检测点激酶1(chk1)抑制剂的3,5-二取代吡唑及其制备及应用
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
CN110678169A (zh) * 2017-03-31 2020-01-10 西雅图遗传学公司 Chk1-抑制剂与weel-抑制剂的组合
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
US12404332B2 (en) * 2020-03-13 2025-09-02 Research Development Foundation Methods for diagnosing and treating cancers

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293552A (en) 1978-02-27 1981-10-06 Eli Lilly And Company Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
US6174993B1 (en) 1997-05-21 2001-01-16 The Children's Medical Center Corp. Short peptides which selectively modulate the activity of serine/threonine kinases
US6218109B1 (en) 1997-09-05 2001-04-17 Baylor College Of Medicine Mammalian checkpoint genes and proteins
GB9718952D0 (en) 1997-09-05 1997-11-12 Medical Res Council Mammalian chk1 effector cell cycle checkpoint protein kinase materials and methods
JP2001518501A (ja) 1997-10-06 2001-10-16 ビーエーエスエフ アクチェンゲゼルシャフト インデノ［１，２−ｃ］−、ナフト［１，２−ｃ］−およびベンゾ［６，７］シクロへプタ［１，２−ｃ］ピラゾール誘導体
EP1135135A4 (en) 1998-09-18 2006-08-09 Smithkline Beecham Corp CHK1 KINASE INHIBITORS
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
WO2001057206A2 (en) 2000-02-03 2001-08-09 Ribozyme Pharmaceuticals, Inc. Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme
US6495586B2 (en) 2000-02-25 2002-12-17 The Regents Of The University Of California Scytonemin and methods of using thereof
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
US6534691B2 (en) 2000-07-18 2003-03-18 E. I. Du Pont De Nemours And Company Manufacturing process for α-olefins
DE60110802T2 (de) 2000-08-18 2005-10-06 Agouron Pharmaceuticals, Inc., San Diego Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
MXPA03006478A (es) 2001-01-26 2003-09-22 Pharmacia Italia Spa Derivados de cromano, procedimiento para su preparacion y su uso como agentes antitumorales.
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
US7064215B2 (en) 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003029241A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003028731A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
EP1448545B1 (en) 2001-10-04 2008-11-19 Smithkline Beecham Corporation Nf-kb inhibitors
JP2005509645A (ja) 2001-10-30 2005-04-14 ファルマシア・コーポレーション 炎症処置用のヘテロ芳香族カルボキサミド誘導体
US20030119839A1 (en) 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003091255A1 (en) 2002-04-26 2003-11-06 Warner-Lambert Company Llc Inhibitors of checkpoint kinases (wee1 and chk1)
US7202244B2 (en) * 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
US7056925B2 (en) * 2002-08-13 2006-06-06 Abbott Laboratories Urea kinase inhibitors
US20040034038A1 (en) 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
EP1539754A4 (en) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOCHINOLINONE AND ITS USE
JP2006508997A (ja) 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用
JP3990718B2 (ja) 2003-01-09 2007-10-17 ファイザー・インク キナーゼ阻害剤としてのジアゼピノインドール誘導体
KR20070028591A (ko) * 2004-06-25 2007-03-12 이코스 코포레이션 Ｃｈｋ1의 억제에 유용한 비스아릴우레아 유도체
CA2679908A1 (en) 2009-09-23 2011-03-23 Shell Internationale Research Maatschappij B.V. Closed loop solvent extraction process for oil sands
CN104407475B (zh) 2014-12-04 2017-04-05 厦门天马微电子有限公司 液晶显示面板

Also Published As

Publication number Publication date
HK1119670A1 (en) 2009-03-13
JP2009227682A (ja) 2009-10-08
MA29439B1 (fr) 2008-05-02
UA92164C2 (ru) 2010-10-11
DK1869020T3 (da) 2011-01-24
JP5117374B2 (ja) 2013-01-16
PL1869020T3 (pl) 2011-05-31
IL185481A0 (en) 2008-01-06
CY1111240T1 (el) 2015-06-11
CA2602199C (en) 2013-09-10
AR056645A1 (es) 2007-10-17
BRPI0609667A2 (pt) 2010-04-20
EP1869020B1 (en) 2010-12-01
US8093244B2 (en) 2012-01-10
ES2356068T3 (es) 2011-04-04
EA200702094A1 (ru) 2008-02-28
CN101151259B (zh) 2011-06-15
CN102219784A (zh) 2011-10-19
NZ561458A (en) 2011-03-31
MX2007012116A (es) 2008-04-08
PT1869020E (pt) 2010-12-23
RS51616B (sr) 2011-08-31
KR20070107178A (ko) 2007-11-06
AU2006230337A1 (en) 2006-10-05
US20090143357A1 (en) 2009-06-04
AU2006230337B2 (en) 2011-10-27
WO2006105262A1 (en) 2006-10-05
TWI375559B (en) 2012-11-01
EA011287B1 (ru) 2009-02-27
KR100912998B1 (ko) 2009-08-20
TNSN07369A1 (en) 2008-12-31
CN101151259A (zh) 2008-03-26
EP1869020A1 (en) 2007-12-26
ZA200707715B (en) 2009-09-30
EP2330105A1 (en) 2011-06-08
KR20090031459A (ko) 2009-03-25
CA2602199A1 (en) 2006-10-05
HRP20100678T1 (hr) 2011-02-28
ATE490248T1 (de) 2010-12-15
CR9395A (es) 2008-03-31
NO20074944L (no) 2007-10-24
TW200722090A (en) 2007-06-16
JP2008535830A (ja) 2008-09-04
SI1869020T1 (sl) 2011-02-28

Similar Documents

Publication Publication Date Title
DE602007006324D1 (de) Insektizide n-substituierte (heteroaryl) cycloalkylsulfoximine
DK2041139T3 (da) Farmaceutiske forbindelser
BRPI0719991A2 (pt) Derivados de di-hidropiridina úteis como inibidores de proteína cinase
NO20073482L (no) Fremgangsmåte til å stabilisere antidement medikament
CY2014012I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
HUS1400051I1 (hu) Lurazidont tartalmazó gyógyászati készítmény
NO20082223L (no) Fremgangsmåte for inhibering av FLT3-kinase
BRPI0716477A2 (pt) Derivados heteroarila como inibidores de quinase protéica
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
ATE440837T1 (de) Indazol-heteroaryl-derivate
ZA200707715B (en) Heteroaryl urea derivatives useful for inhibiting CHK1
DK1957073T3 (da) Lægemiddel
DE602007001593D1 (de) Aryl-/alkylvinylsulfon-hyaluronsäurederivate
DK1937650T3 (da) Heterocykliske forbindelser
SI1942967T1 (sl) Postopek za odmerjanje zdravil
ATE449080T1 (de) 4-phenyl-6-substituierte pyrimidin-2- carbonitrilderivate
ATE487718T1 (de) Substituierte bizyklische pyrimidonderivate
DK1757293T3 (da) Bh4-responsiv hyperphenylalaninæmi-medikamenter
DE602007012260D1 (de) Nitratester von piperidinen
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
DK1910325T3 (da) Nye farmaceutisk forbindelser
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
EP1961750A4 (en) VLA-4-INHIBITORY DRUG
DK1971588T3 (da) Tiglien-3-onderivater

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN